Chimeric antigen receptor (CAR) T-cell therapy is a personalised cancer treatment that is gaining greater visibility and enthusiasm as research advances and success in treating patients is confirmed.
In a simplified way, the production of CAR-T cells works as follows:...
Combatting the backlog in Brazil - prioritising the examination of patent applications
16 Aug 2023
0
In recent years, the Patent Board of the Brazilian Patent and Trademark Office (National Institute of...
READ MORE
TPTO adopts a narrow approach while evaluating bad faith and likelihood of confusion regarding short trade marks
14 Aug 2023
0
The Turkish Patent and Trademark Office (“TPTO”) has recently rendered a significant decision in a trade...
READ MORE
Patenting of stem cells
01 Aug 2023
0
What are stem cells and why are they so important?
The body is an amazing thing, made...
READ MORE
Patent Term Extension (PTE) in Korea provides an opportunity to extend the term of a patent...
READ MORE
Artificial Intelligence – use of emerging AI in patents
09 Jul 2023
0
ChatGPT. DALL·E 2. These are two names, amongst many others, which are at the tips of...
READ MORE
Similar signs are not always confusingly similar
07 Jun 2023
0
The CoC’s decision is valuable as it underscores that it is essential to consider the similarity...
READ MORE
Clare Davis discusses how to cope when feeling overwhelmed. We need to be careful in this...
READ MORE
Divisional applications are a useful tool when considering patent strategy in Brazil. This blog touches on...
READ MORE
BECOME A MEMBER OF FICPI
FICPI is the only international NGO whose membership consists exclusively of IP attorneys in private practice. As a result, the FICPI community is driven by a shared interest to promote solutions and advocacy for private IP practitioners.